| Patients’ cytomegalovirus characteristics | Total |
|---|---|
| N = 52 | |
| CMV Risk, n = 49 (%) | |
| Low risk | 5 (10.2) |
| Intermediate risk | 9 (18.4) |
| High risk | 35 (71.4) |
| Predefined risk strategy, n (%) | |
| Preemptive therapy | 51 (98) |
| Prophylaxis | 1 (2) |
| CMV viremia Post-HSCT, n (%) | |
| Yes | 27 (51.9) |
| No | 25 (48.1) |
| Treatment, n = 27 (%) | |
| Yes | 21 (77.8) |
| No | 6 (22.2) |
| Antiviral, n = 21 (%) | |
| Ganciclovir | 9 (42.9) |
| Valganciclovir | 9 (42.9) |
| Both | 3 (14.3) |
| Viral load (UI/ml), median (range) | 1724.22 (69-12986) |
| Treated | 2064.54 (227-12986) |
| Untreated | 226 (69-319) |
|
Number of PCR per month, median (range) |
4 (1-5) |
| Time to resolution of viremia, median (range) | 107 (7-1804) |
| Post-HSCT cyclophosphamide, n = 15 (%) | |
| Yes | 11 (73.3) |
| No | 4 (26.7) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.